Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gelion gets government grant for lithium-sulfur project

(Sharecast News) - Shares in Gelion surged on Friday after its OXLiD subsidiary was awarded a £533,000 government grant to advance its lithium-sulfur (Li-S) technology. The funding, awarded through the government's DRIVE35 Demonstrate programme which is designed to support advanced manufacturing in the UK, will support scale-up and independent validation of Li-S in so-called 'high-energy multi-layer pouch cells', incorporating Gelion's proprietary sulfur cathode active material (CAM).

This, Gelion said, is an "important step towards market readiness" as it moves towards commercial adoption in defence, aerospace and automotive markets.

Gelion will be working with QinetiQ to build and test the demonstrators incorporating CAM technology, validating performance metrics for these end-markets.

DRIVE35 Demonstrate, delivered through the Advanced Propulsion Centre UK, is putting up half the money for a 12-month £1.1m project, with Gelion's contribution primarily in kind through the provision of time and expertise.

"We are grateful for this government support via the APC to demonstrate how use of our breakthrough Sulfur Cathode Material with Lithium Metal anodes can deliver cells with not only ultra-high energy density but that are also a full set of the other additional performance attributes needed for application to strategic applications like defence and aerospace," said Gelion's chief executive John Wood.

"We are especially pleased to be implementing this alongside QinetiQ utilizing their sector specific experience and UK based cell fabrication capabilities."

Shares were up 13.1% at 21.5p by 0940 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.